HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pancreatectomy

Surgical removal of the pancreas. (Dorland, 28th ed)
Also Known As:
Pancreatectomies
Networked: 6012 relevant articles (268 outcomes, 499 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1. Kang, Chang Moo: 65 articles (06/2022 - 12/2006)
2. Bellin, Melena D: 59 articles (01/2022 - 07/2008)
3. Lee, Woo Jung: 57 articles (06/2022 - 12/2006)
4. Bassi, Claudio: 50 articles (09/2022 - 04/2007)
5. Unno, Michiaki: 46 articles (06/2022 - 01/2007)
6. Yamaue, Hiroki: 42 articles (08/2022 - 11/2002)
7. Büchler, Markus W: 40 articles (12/2022 - 12/2003)
8. Salvia, Roberto: 39 articles (09/2022 - 01/2011)
9. Hwang, Ho Kyoung: 39 articles (06/2022 - 09/2010)
10. Sauvanet, Alain: 37 articles (10/2022 - 09/2002)

Related Diseases

1. Neoplasms (Cancer)
01/01/2022 - "s As a curative surgical procedure for pancreatic neck-body cancer with invasion to celiac artery (CA), the security and efficacy of distal pancreatectomy (DP) with en bloc resection of the celiac artery (DP-CAR) remain controversial. "
01/01/2023 - "The irreversible electroporation with margin accentuation group had significantly greater preoperative stage III (irreversible electroporation 83% vs pancreatectomy alone 51%; P = .0001), with similar tumor location (head 64% vs 72%) and tumor size (median 2.9 vs 2.8). "
01/01/2019 - "Pancreatectomy for malignancy is associated with improved outcomes when performed at high-volume centers. "
01/01/2016 - "Vessel-preserving spleen preservation (SP) during distal pancreatectomy (DP) is supposed to be beneficial for patients with benign and borderline tumors. "
08/01/2015 - "Among the 70 BRPC patients with IVVI, 28 patients (40%) belonged to Group 1, 30 patients (42.9%) belonged to Group 2, and 12 patients (17.1%) belonged to Group 3. Pathological tumor size (P < 0.001), pT stage (P = 0.001), pTNM stage (P=0.002), combined vascular resection (P = 0.003), completeness of adjuvant therapy (P = 0.004) were found to be statistically significantly different between Groups 1 and 2. In addition, disease-free survival (P = 0.055) and disease-specific survival (DSS) (P=0.006) were improved in Group 2. Interestingly, when comparing DSS, there was no statistically significant difference between Groups 1 and 3 (P = 0.991).The clinical practice of pancreatectomy following Neo-CRT in BRPC with IVVI provided favorable oncologic outcomes. "
2. Pancreatic Neoplasms (Pancreatic Cancer)
3. Chronic Pancreatitis
4. Pain (Aches)
5. Pancreatic Fistula (Pancreatic Fistulas)

Related Drugs and Biologics

1. Glucose (Dextrose)
2. Diazoxide (Hyperstat)
3. pasireotide
4. Insulin (Novolin)
5. Gemcitabine
6. Somatostatin (Somatotropin Release-Inhibiting Factor)
7. Octreotide (Sandostatin)
8. Fibrin Tissue Adhesive (Fibrin Sealant)
9. Hormones (Hormone)
10. Glucagon (Glukagon)

Related Therapies and Procedures

1. Autologous Transplantation
2. Pancreaticoduodenectomy
3. Therapeutics
4. Splenectomy
5. Drug Therapy (Chemotherapy)